BL
Therapeutic Areas
Cocrystal Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CC-42344 (Oral PB2 inhibitor) | Influenza A | Phase 2 |
| CC-42344 (Inhaled PB2 inhibitor) | Influenza A | Phase 1 |
| CDI-988 | Norovirus | Phase 1 |
| Pan-viral protease inhibitor | Rhinovirus | Preclinical |
| Oral replication inhibitor | Influenza A & B | Preclinical |
| Undisclosed Program | Hepatitis C | Discovery |
Leadership Team at Cocrystal Pharma
SL
Sam Lee, Ph.D.
Co-Chief Executive Officer and President
JJ
James J. Martin
Co-Chief Executive Officer and Chief Financial Officer
RK
Roger Kornberg, Ph.D.
Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
SR
Steve Rubin
Vice Chairman of the Board
PF
Phillip Frost, M.D.
Director
FH
Fred Hassan
Director
ML
Michael Levitt, Ph.D.
Scientific Advisor, Stanford University, Nobel Laureate
BK
Baek Kim, Ph.D.
Scientific Advisor, Emory School of Medicine
GS
Gary Schoolnik, M.D.
Scientific Advisor, Stanford University School of Medicine
RS
Roland Strong, Ph.D.
Scientific Advisor, Fred Hutchinson Cancer Research Center